Antiphospholipid Antibody Syndrome. (Q53330685)

13 May 2018

title

Antiphospholipid Antibody Syndrome. (English)

1 reference

13 May 2018

author name string

Jacobs BS

series ordinal

1

1 reference

13 May 2018

Levine SR

series ordinal

2

1 reference

13 May 2018

publication date

1 September 2000

1 reference

13 May 2018

Current treatment options in neurology

published in

1 reference

13 May 2018

volume

2

1 reference

13 May 2018

issue

5

1 reference

13 May 2018

page(s)

449-458

1 reference

13 May 2018

IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study

cites work

1 reference

https://api.crossref.org/works/10.1007/S11940-000-0043-9

Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-000-0043-9

Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-000-0043-9

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-000-0043-9

Stroke and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-000-0043-9

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

12 December 2020

Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group

1 reference

12 December 2020

High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events

1 reference

12 December 2020

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry

1 reference

12 December 2020

A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group

1 reference

12 December 2020

Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies

1 reference

12 December 2020

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke

1 reference

12 December 2020

Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies

1 reference

12 December 2020

Anticardiolipin antibodies and their associations with cerebrovascular risk factors

1 reference

12 December 2020

Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome

1 reference

12 December 2020

Intravenous gammaglobulin in a hypothyroid patient with the antiphospholipid antibody syndrome

1 reference

12 December 2020

AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association

1 reference

12 December 2020

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

12 December 2020

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

12 December 2020

Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic 'rheumatic type' valvular heart disease

1 reference

12 December 2020

Prevention of recurrent spontaneous abortion by intravenous immunoglobulin

1 reference

12 December 2020

THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS

1 reference

12 December 2020

Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus

1 reference

12 December 2020

Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options

1 reference

12 December 2020

Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome

1 reference

12 December 2020

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

12 December 2020

A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group

1 reference

12 December 2020

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

1 reference

12 December 2020

Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis

1 reference

12 December 2020

10.1007/S11940-000-0043-9

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018